Printer Friendly

FDA APPROVES NEW DOSAGE FORM OF ELAN'S VERELAN

 FDA APPROVES NEW DOSAGE FORM OF ELAN'S VERELAN
 ATHLONE, Ireland, Jan. 21 /PRNewswire/ -- Elan Corporation, plc


(AMEX: ELN) said it received U.S. FDA marketing approval for a 180 mg strength of Verelan, a patented once-daily formulation of verapamil, one of the most widely prescribed calcium channel blockers for hypertension.
 This drug is licensed to American Cyanamid's Lederle Laboratories division, which began marketing 120 mg capsules and 240 mg capsules of Verelan in July 1990 with American Home Products' Wyeth-Ayerst Laboratories division as co-marketer.
 Verelan utilizes Elan's SODAS technology which provides smooth, consistent absorption regardless of food intake, a more uniform blood pressure response curve, and 24-hour blood pressure control.
 "The approval of the 180 mg once-daily dose expands the availability of Verelan, enabling physicians to further tailor dosing of this fast growing antihypertensive agent to individual patient needs," said Donald E. Panoz, Elan's chairman and chief executive officer.
 The 120 mg strength of Verelan is the lowest starting dose approved for any verapamil formulation. The new 180 mg strength capsule will be available later this month.
 Verelan is manufactured by Elan in Athlone and in Gainesville, Ga., where plans have commenced to increase capacity.
 Elan Corporation, plc is a leader in the specialized health care field of advanced reformulations and drug delivery, concentrating on improved drug absorption and utilization. Elan operates research and manufacturing facilities in Athlone, Republic of Ireland; Gainesville, Ga.; Enschede, Netherlands; Manila, Philippines; Brea, Calif., and Cambridge, Mass.
 -0- 1/21/92
 /CONTACT: Brian Crotty of Elan, 800-252-3526, or Thomas Redington of Redington, Inc., 203-222-7399, or 212-926-1733, for Elan/
 (ELN) CO: Elan Corporation, plc ST: IN: MTC SU:


MK-JS -- NY042 -- 1722 01/21/92 10:34 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 21, 1992
Words:281
Previous Article:SECURITY TRUST'S TERZI TO CHAIR SESTA OPERATIONS COMMITTEE
Next Article:CULLEN/FROST REPORTS FOURTH QUARTER EARNINGS
Topics:


Related Articles
ELAN HEART DRUG LAUNCHING IN EUROPE (Product Announcement)
ELAN TO DOUBLE SIZE OF GAINESVILLE, GA. FACILITY FOR PRODUCTION OF NICOTINE PATCH AND OTHER DRUGS
U.S. FDA APPROVES ELAN'S NICOTINE PATCH
ELAN EARNINGS UP 50 PERCENT THROUGH SECOND QUARTER
WYETH-AYERST LABORATORIES INTRODUCES CONVENIENT NEW DOSAGE OF ANTIHYPERTENSIVE VERELAN (VERAPAMIL HCl)
FDA Grants Approvable Status for Elan's Carbatrol
FDA Approves Elan's Diastat, First Approved At-Home Treatment Specifically for Breakthrough Seizure Clusters
FDA Grants Marketing Authorization for Verelan(R) PM.
Schwarz Pharma and Elan Announce US Launch of Verelan(R) PM.
Elan Announces $40 Million Gainesville Expansion; Georgia to Gain 100 Additional Jobs at Production Facility.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters